Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Cancer Conversations™: Experts Discuss the New Immunotherapy Paradigm in Endometrial Cancer

Watch this on-demand Webcast of a live CCO Webinar in which a panel of international experts discuss the current evidence for immunotherapy for patients with endometrial cancer.

This educational activity is intended for clinicians practicing medicine outside of the United States.

Bradley J. Monk, MD, FACS, FACOG
Program Director
person default
Mansoor Raza Mirza, MD
Prof Isabelle Ray-Coquard, MD, PhD
Released: March 30, 2021

Information on this Educational Activity

Program Director

Bradley J. Monk, MD, FACS, FACOG

Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine--Phoenix
Creighton University School of Medicine at St Joseph's Hospital
Phoenix, Arizona

Bradley J. Monk, MD, FACS, FACOG has disclosed that he has received consulting fees from Agenus, Akeso Bio, Aravive, AstraZeneca, Clovis, Easai, Elevar, Genmab/Seattle Genetics, GOG Foundation, Gradalis, ImmunoGen, Karyopharm, Iovance, Merck, Mersana, Novocure, Myriad, Pfizer, Puma, Roche/Genentech, Sorrento, Tesaro/GSK, and VBL.

Faculty

Mansoor Raza Mirza, MD

Medical Director
Department of Oncology
Chief Oncologist
The Finsen Centre
Rigshospitalet
Copenhagen University Hospital
Copenhagen, Denmark

Mansoor Raza Mirza, MD, has disclosed that he has received consulting fees from AstraZeneca, GlaxoSmithKline, Merck, and Roche; fees for non-CME/CE services from AstraZeneca, GlaxoSmithKline, and Roche, and funds for research support from Apexigen, AstraZeneca Boehringer Ingelheim, Clovis Oncology, Pfizer, Tesaro-GSK, and Ultimovacs.
Prof Isabelle Ray-Coquard, MD, PhD

Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Isabelle Ray Coquard, MD, PhD has disclosed that she has received consulting fees from AstraZeneca, Clovis, Genmab, PharmaMar, Roche, and Tesaro and fees for non-CME/CE services from AstraZeneca, Clovis, PharmaMar, and Tesaro.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.s
Gordon Kelley

Senior Clinical Editor

Gordon Kelley, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Target Audience

This educational program is intended for ex-US gynecologic oncologists, medical oncologists, nurses and other healthcare providers who care for patients with endometrial cancer.

Goal

The goal of this activity is to educate ex-US gynecologic oncologists, medical oncologists, nurses and other healthcare professionals about the recent developments in the use of immunotherapy in the treatment of endometrial cancer and incorporating new data and new therapies into their patient treatment plans.

Program Medium

This program has been made available online.

Related Content

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for gastroesophageal cancers

Manish A. Shah, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Rachna Shroff, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for colorectal cancer (CRC)

John L. Marshall, MD Released: January 21, 2022

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022
Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings